Molecular and Cellular Biochemistry

, Volume 268, Issue 1–2, pp 111–120 | Cite as

Combined treatment of sodium orthovanadate and Momordica charantia fruit extract prevents alterations in lipid profile and lipogenic enzymes in alloxan diabetic rats

  • Umesh C. S. Yadav
  • K. Moorthy
  • Najma Z. Baquer
Article

Abstract

Momordica charantia Linn., commonly called bitter gourd, is a medicinal plant used in the Ayurvedic system of medicine for treating various diseases including diabetes mellitus. Sodium orthovanadate (SOV) is also well-known insulin mimetic and an antidiabetic compound. Our laboratory has been using reduced doses of SOV along with administration of herbal extracts to alloxan diabetic rats and has established this combination as a good antihyperglycemic agent. The present study was undertaken to investigate the effects of treatment of Momordica fruit extract (MFE) and sodium orthovanadate, separately and in combination, on serum and tissue lipid profile and on the activities of lipogenic enzymes in alloxan induced diabetic rats. The results show that there was a significant (p < 0.01) increase in serum total lipids, triglycerides and total cholesterol levels after 21 days of alloxan diabetes. In the liver and kidney of diabetic rats the levels of total lipids and triglycerides also increased significantly (p < 0.01) while levels of total cholesterol decreased significantly (p < 0.01 and p < 0.05, respectively). The lipogenic enzymes showed decreased activity in the diabetic liver, while in kidney they showed an increased activity. When compared with the controls these changes were significant. The treatment of alloxan diabetic rats with MFE and SOV prevented these alterations and maintained all parameters near control values. Most effective prevention was however observed in a combined treatment of Momordica with a reduced dose of SOV (0.2%). The results suggest that Momordica fruit extract and SOV exhibit hypolipidemic as well as hypoglycemic effect in diabetic rats and their effect is pronounced when administered in combination. (Mol Cell Biochem 268: 111–120, 2005)

Key words

alloxan diabetes lipid profile lipogenic enzymes Momordica fruit extract sodium orthovanadate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chaterjea MN, Shinde R: Metabolism of carbohydrate. Part II. In: M.N. Chatterjea (ed). Textbook of Medical Biochemistry, 1st edn. Jay Pee Brothers Medical Publishers Pvt Ltd, India, 1994, p 421Google Scholar
  2. 2.
    Guijarro C, Kasiske BL, Kim Y, O’Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 26(1): 152–161, 1995Google Scholar
  3. 3.
    Chorvathova V, Ondreicka R: The fatty acid composition of the tissues of streptozotocin-diabetic rats. Physiol Bohemoslov 32(5): 466–475, 1983Google Scholar
  4. 4.
    Sochor S, Baquer NZ, Ball MR, McLean P: Regulation of enzymes of glucose metabolism and lipogenesis in diabetic rat liver by thyroid hormones. Biochem Int 15(3): 619–627, 1987Google Scholar
  5. 5.
    Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 36(2): 67–75, 1991Google Scholar
  6. 6.
    Sun L, Halaihel N, Zhang W, Rogers T, Levi M: Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277(21): 18919–18927, 2002Google Scholar
  7. 7.
    Welihinda J, Karunanayake EH, Sheriff MH, Jayasinghe KS: Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 17(3): 277–282, 1986Google Scholar
  8. 8.
    Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J: Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the Streptozotocin diabetic rat. Diabetes Res Clin Pract 40: 145–151, 1998Google Scholar
  9. 9.
    Platel K, Shurpalekar KS, Srinivasan K: Influence of bitter gourd (Momordica charantia) on growth and blood constituents in albino rats. Nahrung 37(2): 156–160, 1993Google Scholar
  10. 10.
    Jayasooriya AP, Sakono M, Yukizaki C, Kawano M, Yamamoto K, Fukuda N: Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol 72(1–2): 331–336, 2000Google Scholar
  11. 11.
    Ahmed I, Lakhani MS, Gillett M, John A, Raza H: Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 51(3): 155–161, 2001Google Scholar
  12. 12.
    Heyliger CE, Tahiliani AJ, McNeill JH: Effects of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474–1476, 1985Google Scholar
  13. 13.
    Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats: Characterization and mode of action. J Biol Chem 262(14): 6658–6662, 1987Google Scholar
  14. 14.
    Brichard SM, Okitolonda W, Henequin JC: Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123: 2048–2053, 1988Google Scholar
  15. 15.
    Sakurai H, Tsuchiya K, Nukatsuka M, Sofue M, Kawada J: Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. J Endocrinol 126(3): 451–459, 1990Google Scholar
  16. 16.
    Cam MC, Pederson RA, Brownsey RW, McNeill JH: Long-term effectiveness of oral vanadyl sulphate in streptozotocin diabetic rats. Diabetologia 36: 218–224, 1993Google Scholar
  17. 17.
    Pugazhenthi S, Hussain A, Yu B, Brownsey RW, Angel JF, Khandelwal RL: Vanadate induces normolipidemia and a reduction in the levels of hepatic lipogenic enzymes in obese Zucker rat. Mol Cell Biochem 153(1–2): 211–215, 1995Google Scholar
  18. 18.
    Srivastava AK: Antidiabetic and toxic effects of vanadium compounds. Mol Cell Biochem 206(1–2): 177–182, 2000Google Scholar
  19. 19.
    Thompson KH, Liboiron BD, Sun Y, Bellman KD, Setyawati IA, Patrick BO, Karunaratne V, Rawji G, Wheeler J, Sutton K, Bhanot S, Cassidy C, McNeill JH, Yuen VG, Orvig C: Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. J Biol Inorg Chem 8(1–2): 66–74, 2003Google Scholar
  20. 20.
    Brichard SM, Ongemba LN, Girard J, Henequin JC: Tissue specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate. Diabetologia 37: 1065–1072, 1994Google Scholar
  21. 21.
    Yuen VG, Orvig C, McNeill JH: Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Can J Physiol Pharmacol 71(3–4): 263–269, 1993Google Scholar
  22. 22.
    Ramanadham S, Mongold JJ, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257(3 Pt 2): H904–H911, 1989Google Scholar
  23. 23.
    Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 188(1–2): 73–80, 1998Google Scholar
  24. 24.
    Dafnis E, Sabatini S: Biochemistry and pathology of vanadium. Nephron 67: 133–143, 1994Google Scholar
  25. 25.
    Domingo JL, Vanadium and tungsten derivatives as antidiabetic agents: A review of their toxic effects. Biol Trace Elem Res 88(2): 97–112, 2002Google Scholar
  26. 26.
    Nandhini D, Maneemegalai S, Elangovan V, Sekar N, Govindasamy S: Insulin-like effects of bis-glycinato oxovanadium (IV) complex on experimental diabetic rats. Indian J Biochem Biophys 30(1): 73–76, 1993Google Scholar
  27. 27.
    Sochor M, Baquer NZ, McLean P: Glucose over and underutilization in diabetes: Comparative studies on the changes in activities of enzymes of glucose metabolism in rat kidney and liver. Mol Physiol 7: 51–68, 1985Google Scholar
  28. 28.
    Baquer NZ, Cascales M, Mclean P, Greenbaum AL: Effects of thyroid deficiency on the distribution of hepatic metabolism and control of pathways of carbohydrate metabolism in liver and adipose tissue of the rat. Eur J Biochem 68: 403–413, 1976Google Scholar
  29. 29.
    Saggerson ED, Greenbaum AL: The regulation of triglyceride synthesis and fatty acid synthesis in rat epididymal adipose tissue. Biochem J 119: 221–242, 1970Google Scholar
  30. 30.
    Srere PA: The citrate enzymes: Their structures, mechanisms, and biological functions – A review. Curr Top Cell Regul 5: 229–283, 1972Google Scholar
  31. 31.
    Folch J, Lees M, Stanley GHS: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497–509, 1957PubMedGoogle Scholar
  32. 32.
    Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with folin phenol reagent. J Biol Chem 193: 265–275, 1951PubMedGoogle Scholar
  33. 33.
    Grover JK, Vats V, Rathi SS, Dawar R: Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. J Ethnopharmacol 76(3): 233–238, 2001Google Scholar
  34. 34.
    Gupta D, Raju J, Prakash J, Baquer NZ: Change in the lipid profile, lipogenic and related enzymes in the livers of experimental diabetic rats: Effect of insulin and vanadate. Diabetes Res Clin Pract 46(1): 1–7, 1999Google Scholar
  35. 35.
    Day C, Cartwright T, Provost J, Bailey CJ: Hypoglycaemic effect of Momordica charantia extracts. Planta Med 56(5): 426–429, 1990Google Scholar
  36. 36.
    Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J: Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102(3): 619–624, 1998Google Scholar
  37. 37.
    Peterson DT, Green WC, Reaven GM: Effect of experimental diabetes mellitus on kidney ribosomal protein synthesis. Diabetes 20: 649–654, 1971Google Scholar
  38. 38.
    Raju J, Gupta D, Rao AR, Yadava PK, Baquer NZ: Trigonella foenum-graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem 224(1–2): 45–51, 2001Google Scholar
  39. 39.
    Scott M, Grundy: Diabetes and cardiovascular disease. Circulation 100: 1134–1146, 1999Google Scholar
  40. 40.
    Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL: Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96(24): 13656–13661, 1999Google Scholar
  41. 41.
    West KM: Hyperglycemia as a cause of long-term complications. In: H. Keen, J. Jarret (eds). Complications of Diabetes, 2nd edn. Jarret Edward Arnold, London, 1982, pp 3–18Google Scholar
  42. 42.
    Ramakrishna S, Murthy KS, Benjamin WB: Effect of insulin on ATP-citrate lyase phosphorylation. Regulation of peptide A and peptide B phosphorylation. Biochemistry 28: 856–860, 1989Google Scholar
  43. 43.
    Sahng-Wook P, Kyung-Sup K, Suk-Kuy W, Jin-Soo K, Yoon-Soo K: Induction of hepatic ATP-citrate lyase by insulin in diabetic rats. Yonsei Med J 35(1): 25–33, 1994Google Scholar
  44. 44.
    Sato R, Okamoto A, Inoue J, Miyamoto W, Sakai Y, Emoto N, Shimano H, Maeda M: Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins. J Biol Chem 275(17): 12497–12502, 2000Google Scholar
  45. 45.
    Moon YA, Lee JJ, Park SW, Ahn YH, Kim KS: The roles of sterol regulatory element-binding proteins in the transactivation of the rat ATP citrate-lyase promoter. J Biol Chem 275(39): 30280–30286, 2000Google Scholar
  46. 46.
    Lakshmanan MR, Nepokroeff CM, Porter JW: Control of the synthesis of fatty acid synthetase in rat liver by insulin, glucagon and adenosine-3′ 5′ cyclic monophosphate. Proc Natl Acad Sci USA 69(12): 3516–3519, 1972Google Scholar
  47. 47.
    Sakurai H: A new concept: The use of vanadium complexes in the treatment of diabetes mellitus. Chem Rec 2(4): 237–248, 2002CrossRefPubMedGoogle Scholar
  48. 48.
    Shinde UA, Mehta AA, Goyal RK: Effect of chronic treatment with bis(maltolato)oxovanadium (IV) in rat model of non-insulin dependent diabetes. Indian J Exp Biol 39: 864–870, 2001Google Scholar
  49. 49.
    Yadav UCS, Moorthy K, Baquer NZ: Effects of sodium orthovanadate and Trigonella foenum-graecum seed on hepatic and renal lipogenic enzymes and lipid profile during alloxan diabetes. J Biosci 29: 81–91, 2004Google Scholar
  50. 50.
    Sarkar S, Pranava M, Marita R: Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 33(1): 1–4, 1996Google Scholar
  51. 51.
    Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I: Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo) 47(5): 340–344, 2001Google Scholar
  52. 52.
    Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM, Biyani MK: Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol 88(1): 107–111, 2003Google Scholar
  53. 53.
    Singh N, Tyagi SD, Agarwal SC: Effects of long term feeding of acetone extract of Momordica charantia (whole fruit powder) on alloxan diabetic albino rats. Indian J Physiol Pharmacol 33(2): 97–100, 1989Google Scholar
  54. 54.
    Ahmad N, Hassan MR, Halder H, Bennoor KS: Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 25(1): 11–13, 1999Google Scholar
  55. 55.
    Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH: Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) 282(6279): 1823–1824, 1981Google Scholar
  56. 56.
    Rathi SS, Grover JK, Vats V: The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother Res 16(3): 236–243, 2002Google Scholar
  57. 57.
    Kar A, Choudhary BK, Bandyopadhyay NG: Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in alloxan diabetic rats. J Ethnopharmacol 84(1): 105–108, 2003Google Scholar
  58. 58.
    Sitasawad SL, Shewade Y, Bhonde R: Role of bittergourd fruit juice in stz-induced diabetic state in vivo and in vitro. J Ethnopharmacol 73(1–2): 71–79, 2000Google Scholar
  59. 59.
    Shibib BA, Khan LA, Rahman R: Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: Depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 292(Pt 1): 267–270, 1993Google Scholar
  60. 60.
    Vikrant V, Grover JK, Tandon N, Rathi SS, Gupta N: Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J Ethnopharmacol 76(2): 139–143, 2001Google Scholar
  61. 61.
    Ng TB, Wong CM, Li WW, Yeung HW: Acid–ethanol extractable compounds from fruits and seeds of the bitter gourd Momordica charantia: Effects on lipid metabolism in isolated rat adipocytes. Am J Chin Med 15(1–2): 31–42, 1987Google Scholar
  62. 62.
    Khanna P, Jain SC, Panagariya A, Dixit VP: Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 44(6): 648–655, 1981Google Scholar
  63. 63.
    Ng TB, Wong CM, Li WW, Yeung HW: Insulin-like molecules in Momordica charantia seeds. J Ethnopharmacol 15(1): 107–117, 1986Google Scholar

Copyright information

© Kluwer Academic Publishers 2005

Authors and Affiliations

  • Umesh C. S. Yadav
    • 1
  • K. Moorthy
    • 1
  • Najma Z. Baquer
    • 1
  1. 1.Hormone and Drug Research Laboratory, School of Life SciencesJawaharlal Nehru UniversityNew DelhiIndia

Personalised recommendations